drugset / Trial / NCT02608216

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

NCT02608216

Phase 1 Active not recruiting 20 enrolled University of Pennsylvania
NaSingle-groupOpen-labelDiagnostic

Summary

In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluorothymidine (FLT).

Timeline

Start
2015-11
Primary completion
2026-11
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Background Paclitaxel Small molecule
Background Ribociclib Small molecule

Indications